Eschew Enhancement

April 21, 2009

In an effort to provide Alzheimer’s and schizophrenia patients with better, safer medicines, biotech and big pharma have embarked on drug discovery programs targeting multiple cognitive mechanisms. Several of the resulting medications have progressed to late-stage clinical development. For patients suffering from these diseases, the new drugs have the potential to improve cognitive function over a longer term than available treatments, which fade in effectiveness over time. (Technology Review)